同步放化疗治疗子宫颈癌的临床分析

目的比较放疗期间增敏化疗和单纯放射治疗中、晚期子宫颈癌的疗效及不良反应。方法65例中、晚期子宫颈癌患者被随机分为治疗组（33例）和对照组（32例）：治疗组在放疗期间加增敏化疗2个疗程，在放疗的第1个周期开始PF方案（顺铂＋5-氟尿嘧啶）化疗，放疗4—6周后，再行第2个疗程的化疗。对照组单纯进行放疗。结果治疗组和对照组的近期有效率分别为100％和91％；治疗组1、2年生存率分别为80％、66％；对照组1、2年生存率分别为73％、31％；局部复发率分别为9％和31％；两组患者的不良反应均为白细胞减少、放射性直肠炎和放射性膀胱炎，其发生率近似。但Ⅲ-Ⅳ度血液反应发生率分别为12％和9％。结论放疗期间加2个疗程的增敏化疗对子宫颈癌具有较好的疗效。

A clinical analysis of cervical cancer treatment with concurrent chemoradlation

Objective To Compare the effect and side effect of middle and advanced cervical cancer between sensitizing chemotherapy and radiotherapy. Methods 65 cervical cancer patients were randomly divided into two set: treatment (33) and comparison (32). During radiotherapy, the treatment set was added two courses of sensitizing chemotherapy, where the first one began the first radiotherapy week and the second one began after four-to-six weeks. The chemotherapy scheme was PF. The comparison set only received radiotherapy. Results The short effective rate of treatment set and comparison set was 100 % and 91% respectively, and one year survival rate of them was 80 % and 66 %, two year 73 % and 31 %, the local recurrent rate 9 % and 31 %. Grade 3-4 acute leucopenia rate was 9 % and 13 %. The side effects of two sets were white blood cells decrease, radiation pmctitis and radiocystitis, and these results were similar. Conclusion The method of two cycles sensitizing chemotherapy during radiotherapy has better treatment effect for cervical cancer.